PFE · Earnings call · 2026Q3T · Full report
Revenue Performance and Mix
PFIZER INC · 2026-11-03 · Importance 38 · Surprise 24 · No source text
CEO Albert Bourla said Nurtec was close to $2 billion on an annualized basis, while the Street forecast it to reach almost $2.5 billion by 2030. He contrasted a $5 billion Street forecast for a competing product with a $600 million forecast for Pfizer’s Elrexfio, which management said it believes is not justified by current information. Pfizer expects new and acquired products, including pipeline products in obesity and oncology, to contribute to its longer-term growth trajectory.
Key facts
- Pfizer's launched and acquired products generated $3.8 billion in Q3 2026 revenue and grew 32% operationally.
- Pfizer's Q3 2026 revenue was $16.7 billion, with 7% operational growth from non-COVID products, offset by lower COVID-19 product revenue.
- Pfizer's launched and acquired products grew 32% operationally in Q3 2026.
- Pfizer's acquired products grew 37% operationally in Q3 2026.
- Biohaven grew 33% operationally for Pfizer in Q3 2026.
- Pfizer's Q3 2026 reported diluted EPS was $0.56 and adjusted diluted EPS was $0.87.
- In Q3 2026, Padcev generated $255 million, Nurtec $135 million, and Lorbrena $114 million for Pfizer.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +5.6% | Pfizer's launched and acquired products generated $3.8 billion in Q3 2026 revenue and grew 32% operationally. |
| revenue | positive | realized | — | Pfizer's Q3 2026 revenue was $16.7 billion, with 7% operational growth from non-COVID products, offset by lower COVID-19 product revenue. |
| revenue | negative | realized | — | Pfizer's Q3 2026 revenue was $16.7 billion, with 7% operational growth from non-COVID products, offset by lower COVID-19 product revenue. |